Showing results (91-100 of 151) with videos related to
Sort By:
Pageof 16
Cancer Medicine|August 4, 2016
An analysis of the relationship between metastases and cachexia in lung cancer patientsMasatoshi Shiono, Kan Huang, Robert J Downey, et al.Frontiers in Oncology|July 3, 2020
Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast CancerDouglas K Marks, Robyn D Gartrell, Margueritta El Asmar, et al.Breast Cancer Research and Treatment|June 25, 2021
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancerMatthew Kearney, Lauren Franks, Shing Lee, et al.Breast Cancer Research and Treatment|June 7, 2014
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancerYifan Tu, Dawn L Hershman, Kapil Bhalla, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2022
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline UpdateFabrice Andre, Nofisat Ismaila, Kimberly H Allison, et al.Breast Cancer Research and Treatment|May 11, 2022
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancerJoyce O'Shaughnessy, Adam Brufsky, Hope S Rugo, et al.Breast Cancer Research and Treatment|December 7, 2023
Randomized adaptive selection trial of cryotherapy, compression therapy, and placebo to prevent taxane-induced peripheral neuropathy in patients with breast cancerMelissa K Accordino, Shing Lee, Cheng Shiun Leu, et al.EMBO Molecular Medicine|July 2, 2024
FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancerYifan Tai, Angela Chow, Seoyoung Han, et al.Genes & Development|August 1, 2015
Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancersRuth Rodriguez-Barrueco, Jiyang Yu, Laura P Saucedo-Cuevas, et al.NPJ Breast Cancer|August 29, 2022
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancerHope S Rugo, Sara M Tolaney, Delphine Loirat, et al.Pageof 16